CryoPort (NASDAQ:CYRX) & Alpha Teknova (NASDAQ:TKNO) Head-To-Head Contrast

Alpha Teknova (NASDAQ:TKNO) and CryoPort (NASDAQ:CYRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.

Profitability

This table compares Alpha Teknova and CryoPort’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-38.37%	-24.94%	-16.53%
CryoPort	-20.05%	-7.20%	-4.30%

Earnings & Valuation

This table compares Alpha Teknova and CryoPort”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Teknova	$43.70 million	10.96	-$17.26 million	($0.31)	-28.81
CryoPort	$176.18 million	5.03	$78.30 million	($0.90)	-19.43

CryoPort has higher revenue and earnings than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Alpha Teknova and CryoPort, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	1	1	3	0	2.40
CryoPort	1	1	7	0	2.67

Alpha Teknova presently has a consensus price target of $8.00, suggesting a potential downside of 10.41%. CryoPort has a consensus price target of $18.00, suggesting a potential upside of 2.92%. Given CryoPort’s stronger consensus rating and higher possible upside, analysts clearly believe CryoPort is more favorable than Alpha Teknova.

Volatility and Risk

Alpha Teknova has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, CryoPort has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500.

Insider and Institutional Ownership

13.8% of Alpha Teknova shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 13.2% of Alpha Teknova shares are owned by insiders. Comparatively, 9.5% of CryoPort shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

CryoPort beats Alpha Teknova on 11 of the 14 factors compared between the two stocks.

About Alpha Teknova

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

About CryoPort

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.